| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,515 | 0,590 | 27.02. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | ADVANCE ZINCTEK LIMITED: Half Yearly Report and Accounts | - | ASX | ||
| Fr | ADVANCE ZINCTEK LIMITED: Appendix 4D | - | ASX | ||
| 16.02. | XFRA CAPITAL ADJUSTMENT INFORMATION - 16.02.2026 | 501 | Xetra Newsboard | Das Instrument OYS US68162K1060 OLYMPIC STEEL EQUITY wird cum Kapitalmassnahme gehandelt am 16.02.2026 und ex Kapitalmassnahme am 17.02.2026 The instrument OYS US68162K1060 OLYMPIC STEEL EQUITY is traded... ► Artikel lesen | |
| ADVANCE ZINCTEK Aktie jetzt für 0€ handeln | |||||
| 13.02. | ADVANCE ZINCTEK LIMITED: Capital Return Update | 2 | ASX | ||
| 12.02. | ADVANCE ZINCTEK LIMITED: Return of Capital - ANO | 1 | ASX | ||
| 09.01. | ADVANCE ZINCTEK LIMITED: FDA Update | 1 | ASX | ||
| 12.12.25 | ADVANCE ZINCTEK LIMITED: Response to Television Broadcast Early This Week | - | ASX | ||
| 09.12.25 | ADVANCE ZINCTEK LIMITED: Change of Director's Interest Notice - Lev Mizikovsky | 1 | ASX | ||
| 08.12.25 | ADVANCE ZINCTEK LIMITED: Change of Director's Interest Notice - Lev Mizikovsky | - | ASX | ||
| 05.12.25 | ADVANCE ZINCTEK LIMITED: Change of Director's Interest Notice - Lev Mizikovsky | - | ASX | ||
| 28.11.25 | ADVANCE ZINCTEK LIMITED: Change of Director's Interest Notice - Lev Mizikovsky | - | ASX | ||
| 17.11.25 | ADVANCE ZINCTEK LIMITED: FDA Inspection Update | - | ASX | ||
| 14.11.25 | ADVANCE ZINCTEK LIMITED: Results of Meeting | 1 | ASX | ||
| 13.11.25 | ADVANCE ZINCTEK LIMITED: Chair's Presentation to Shareholders | - | ASX | ||
| 17.10.25 | ADVANCE ZINCTEK LIMITED: Notice of Annual General Meeting/Proxy Form | 1 | ASX | ||
| 02.10.25 | ADVANCE ZINCTEK LIMITED: Improvement of 26.83% in First Quarter Revenue - FY26 | 2 | ASX | ||
| 26.09.25 | ADVANCE ZINCTEK LIMITED: Statement Regarding US Pharmaceutical Tariffs | - | ASX | ||
| 03.09.25 | ADVANCE ZINCTEK LIMITED: Response to Rumours Re CHOICE Sunscreen Test Findings | 1 | ASX |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 22,950 | +0,44 % | EQS-News: Formycon AG: Formycon gibt positive klinische Daten für den Keytruda-Biosimilar-Kandidaten FYB206 (Pembrolizumab) bekannt | EQS-News: Formycon AG
/ Schlagwort(e): Studienergebnisse/Studie
Formycon gibt positive klinische Daten für den Keytruda-Biosimilar-Kandidaten FYB206 (Pembrolizumab) bekannt
25.02.2026... ► Artikel lesen | |
| RIBER | 5,790 | -2,03 % | RIBER: 2025 performance driven by production systems and the rollout of ROSIE | 2025 performance driven by production systems and the rollout of ROSIE Revenues of €40.3 million in line with guidanceOrder book at December 31, 2025: €26.9 million (+24%) Bezons (France), February... ► Artikel lesen | |
| GOMSPACE | 1,688 | -1,86 % | GomSpace Group AB: GomSpace Reports an all-time high Q4 and a full year of significant growth | GomSpace delivers all-time high revenue, threefold growth in EBITDA, and secures major contracts for 2026, supported by a strong year-end balance sheet and cash position, as well as a 12% backlog increase... ► Artikel lesen | |
| ONTO INNOVATION | 185,00 | +1,09 % | ONTO INNOVATION INC. - 10-K, Annual Report | ||
| SOLESENCE | 1,260 | -4,91 % | Solésence, Inc.: Solésence Reports Third Quarter 2025 Financial Results | Advances Strategic Transformation with Key Changes in Executive Leadership, Product Development and Operations ROMEOVILLE, Ill., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN)... ► Artikel lesen | |
| CANATU | 9,400 | +1,95 % | Canatu Oyj: Canatu and DENSO enter Joint Development Agreement to develop large-scale CNT chamber, supporting potential automotive applications such as full windshield heaters | Canatu Plc Press release 2 January 2026 at 09:00 am EET
Canatu and DENSO enter Joint Development Agreement to develop large-scale CNT chamber, supporting potential automotive applications such as full... ► Artikel lesen | |
| VEECO INSTRUMENTS | 25,800 | -0,77 % | Veeco Instruments Inc.: Veeco Announces Upcoming Investor Events | ||
| NANOVEU | 0,048 | +24,10 % | NANOVEU LIMITED: Appendix 4G & Corporate Governance Statement | ||
| GAUZY | 0,500 | -1,96 % | Gauzy Ltd. Announces Receipt of Nasdaq Notice Regarding Board Composition Requirements | TEL AVIV, Israel, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Gauzy Ltd. (NASDAQ: GAUZ) ("Gauzy" or the "Company"), a global leader in vision and light control technologies, today announced that it has received... ► Artikel lesen | |
| NVE | 60,00 | +2,56 % | Dividendenbekanntmachungen (02.02.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACUITY INC US00508Y1029 0,2 USD 0,1687 EUR ALLY FINANCIAL INC US02005N1000 0,3 USD 0,2531 EUR AMERISERV FINANCIAL INC US03074A1025 0... ► Artikel lesen | |
| OBDUCAT | 0,006 | +77,78 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.12.2025 | Das Instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 31.12.2025 und ex Kapitalmassnahme am 02.01.2026 The instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY... ► Artikel lesen | |
| KOPIN | 1,843 | 0,00 % | Kopin Corporation: Michael Murray, Kopin's CEO to Present at THEON International's Capital Markets Day (CMD) on November 6, 2025 | Kopin Corporation (NASDAQ: KOPN), a leading provider of application-specific optical systems and high-performance microdisplays for defense, training, enterprise, industrial, consumer and medical... ► Artikel lesen | |
| ACACIA RESEARCH | 3,460 | +2,98 % | ACACIA RESEARCH CORP - 8-K, Current Report | ||
| LAMPETIA | 0,094 | 0,00 % | EQS-News: Lampetia AG: Halbjahresfinanzbericht auf neuer Webseite | EQS-News: Lampetia AG
/ Schlagwort(e): Halbjahresbericht
LAMPETIA AG: Halbjahresfinanzbericht auf neuer Webseite
30.09.2025 / 19:51 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| NANOVIRICIDES | 0,760 | -3,80 % | MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides | SHELTON, CONNECTICUT / ACCESS Newswire / February 12, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the... ► Artikel lesen |